

Environmental Science Processes & Impacts

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



rsc.li/process-impacts

ECETOC TRA version 3 : Capturing and Consolidating the Experiences of REACH

1 **Perspectives Article**

2

3 **ECETOC TRA version 3 : Capturing and Consolidating the Experiences of REACH**

4

5 Chris Money^a, Frank Schnoeder^b, Dook Noij^c, Hsieng-Ye Chang^d, and Jan Urbanus^e

6

7 ^a ExxonMobil Biomedical Sciences, Fawley, United Kingdom, +44 (0)2380 895090 (phone), +44 (0)2380
8 895325 (fax), chris.money@exxonmobil.com (email)

9 ^b DuPont de Nemours (Deutschland) GmbH, Neu-Isenburg, Germany, +49 (0)2241 2390640 (phone),
10 frank.schnoeder@dupont.com (email)

11 ^c Dow Chemical, Terneuzen, Netherlands, + 31 115 67 38 14 (phone) dook.noij@dow.com (email)

12 ^d DuPont Coordination Center, Mechelen, Belgium +32 (0)2 663 5982 (phone), +32 (0)2 660 9323,
13 hsieng.y.chang@dupont.com (e-mail)

14 ^e Shell Health, Brussels, Belgium, +32 (0)2 5089489 (phone), jan.urbanus@shell.com (e-mail)

15

16

17

18 **Word count** : abstract : 187 contents : 4256 reference # : 18

19

20

21

22 **Key words**: REACH, exposure assessment, exposure prediction, modelling, TRA

23

24

ECETOC TRA version 3 : Capturing and Consolidating the Experiences of REACH

25 **Abstract**

26 The ECETOC Targeted Risk Assessment (TRA) model is intended to evaluate the nature of human and
27 environmental exposures and risks arising from the manufacture and use of chemicals and version2 has
28 been extensively applied to develop Chemical Safety Assessments for substances registered under Phase
29 1 of REACH. In order to maintain the model, ECETOC solicited suggestions from TRA users arising from
30 their experiences gained from its use in the 2009-2011 period. TRA users identified 16 different ways in
31 which the worker exposure predictions of the TRA might be further improved at the technical level. The
32 suggestions can be divided into those that are capable of being incorporated into the model and those
33 which cannot which, in turn, appear to be reflective of the wide range of technical understandings of
34 users of Tier 1 REACH models such as the TRA. The consequence of such user heterogeneity presents
35 challenges for model developers, particularly those models intended for inclusion in regulatory
36 processes. Those considerations that are relevant for the revision to the worker portion of the TRA
37 (version3) are described, together with their potential relevance for other REACH exposure models.

38 Background

39 The European REACH regulation [1] requires the documentation of safe conditions of use for classified
40 chemical substances during their entire life-cycle, from manufacture, via distribution and formulation, to
41 a series of end uses which can be extensive for commodity substances such as solvents. The regulation
42 introduced the concept of the 'Exposure Scenario' (ES) for each use in the life-cycle where the ES refers
43 to the Risk Management Measures (RMMs) required to be applied to ensure safe use under defined
44 Operational Conditions (OCs) of the use. 'Safe use' implies that exposure levels (inhalation and dermal in
45 the case of workers) are below specified reference values. Within each use there are likely to be
46 distinctly different activities (tasks) requiring specific RMMs, resulting in a multitude of Chemical Safety
47 Assessments (CSA) that are required to build up a REACH registration dossier for a substance.

48 The ECETOC Targeted Risk Assessment (TRA) model is intended to evaluate the nature of human and
49 environmental exposures and risks arising from the manufacture and use of chemicals and was launched
50 in 2003 [2]. For human health, the TRA model can estimate both worker and consumer exposures,
51 together with the ability to incorporate defined reference values (such as OELs) in order to gauge the
52 nature of risk. The original aim of the TRA was, in the discussions leading up to what eventually became
53 the EU REACH Regulation, to demonstrate the utility of tiered and targeted approaches for the risk
54 assessment of chemicals i.e. the application of a series of models (Tiers) that together serve as a suitably
55 conservative screen for identifying where ('targeting') the application of more detailed (higher Tier)
56 approaches is appropriate [3]. Such tiered approaches to the use of exposure estimates in the
57 evaluation of workplace risks build from established occupational hygiene practice and hence are
58 equally applicable to assessments under worker health protection regulations as well as under REACH.
59 In this respect, the original TRA (version1) used the concept of the 'exposure scenario' to help users
60 differentiate and focus on those workplace use conditions that are likely to represent those of most
61 concern.

62 The concepts of tiering and targeting, together with that of the 'exposure scenario', subsequently
63 became enshrined within the REACH Regulation, as well as its supporting Technical Guidance. For
64 example, the origin of the Use Descriptors (such as Process Categories, PROCs, and Product Categories,
65 PCs) that now form the basis of how uses are described and communicated within REACH [4] can be
66 directly traced to the terms used to describe worker and consumer exposure in TRA v1. However, as the
67 discussions on the form and content of REACH developed during 2003-2005, it also became apparent
68 that certain elements of TRA v1 were either insufficient to meet some of the demands of REACH or had
69 become redundant altogether [5]. Specifically, in order to accommodate potential data gaps in the
70 understanding of a substance's hazardous properties, parts of the TRA v1 reflected 'hazard and risk
71 banding' concepts such as those contained in the UK HSE's COSHH Essentials tool [6] whereas REACH is
72 clear in its requirement that substance risk assessments must be based on the specific hazards of the
73 chemical and not any generic assumptions. Furthermore, it also became apparent that version 1 was
74 insufficient to address the necessary scope and level of detail expected of worker risk assessments
75 under REACH [7]. As a consequence, ECETOC significantly revised v1 and released version 2 in 2009. This
76 meant that version 2 better reflected the requirements of REACH as described in the legal text and its

77 supporting Technical Guidance, particularly its ability to predict inhalation and dermal exposures for
78 relevant conditions of use (and described using Process Categories (or PROCs)). At the same time, the
79 tool's layout was also developed to allow ready access by the range of user skill types implied by its use
80 in REACH Chemical Safety Assessments i.e. ranging from manufacturers and formulators to downstream
81 users of chemicals. Version 2 has been available for free download from the ECETOC website, together
82 with supporting materials that enable users to correctly install the tool and understand its limitations
83 [8]. The current REACH technical Guidance identifies the TRA as the "preferred Tier 1" tool for worker
84 exposure estimation [9]. Over 14,000 downloads of the TRA v2 tool have been made from the TRA
85 website since May 2009 and the TRAv2 has been used as the basis for estimating worker exposures in
86 the significant majority (greater than 80%) of those Phase 1 (2010) REACH Registrations that were
87 required to be supported by a Chemical Safety Assessment [10].

88 Following the completion of Phase 1 of REACH in December 2010 (substances in commerce at >1000
89 tpa), ECETOC approached users of the TRA to seek their ideas for how the TRA might be further
90 improved. The aim of this exercise was to ensure that key learnings arising from the use of the TRA in
91 2009/10 could be captured, evaluated and incorporated into an updated version that would be intended
92 to be available for use in Phase 2 of REACH (registration of substances in the tonnage range 100-1000
93 tpa by 1st June 2013). The intention was to characterize the nature of any shortcomings in TRA v2 in
94 order to identify the extent to which the TRA needed to be further improved. At around the same time,
95 the European Chemicals Agency (ECHA) also announced its intention to release a revised version of its
96 Chesar CSA tool by Summer 2012, in order that Chesar was able to incorporate many of the solutions to
97 the challenge of CSA/ES development and communication that had become available subsequent to the
98 initial release of Chesar (for example the substance use maps and generic exposure scenarios developed
99 within the key chemical supply chains [11]). For human health scenarios, Chesar v1 applied the TRA v2
100 exposure estimates. ECHA therefore asked ECETOC to ensure that any developments to the TRA were
101 also undertaken on a timescale that was consistent with ECHA's desire to have available a revised
102 version of Chesar before the summer of 2012.

103

104 **Methods**

105 Free download of the TRA is possible after potential users have registered some basic details on the
106 ECETOC website (<http://www.ecetoc.org/tra>). This step enables ECETOC to maintain a listing of TRA
107 users in order to make them aware of TRA-related developments, but no information is captured on the
108 demographics of the user or the reasons why they are seeking access to the TRA. In the case of TRA v1
109 (which was a web-based application), ECETOC's vision was that this 'community' might be stimulated to
110 become proactive in collaboratively solving questions on the use of the TRA, as well as proposing ideas
111 on its further development. But this level of ambition exceeded reality, so this functionality was
112 withdrawn in TRA v2.

113 In order to ascertain the extent to which further development of the TRAv2 was appropriate, ECETOC
114 contacted all registered TRA users in late 2010, explaining its reasons for wanting to review the TRA v2

115 and soliciting their experiences of its use and suggestions for how it might be further improved. Around
116 120 responses were received. These were mostly from larger European companies, but also included
117 regulatory agencies and smaller consulting organisations. ECETOC then compiled an inventory of the
118 various experiences and suggestions it had received and used this as a major input to a one day
119 workshop that was held in March 2011 at which the proposals was discussed in order to identify those
120 suggestions that had the potential to be taken forward for incorporation into version3 of the TRA.
121 Moreover, as ECHA's vision for Chesar v2 (<http://chesar.echa.europa.eu/home>) evolved, especially
122 regarding its planned functionality and data dependencies, discussions also took place with ECHA, in
123 order to ensure TRA-related enhancements could also be accommodated within Chesar (and vice versa).

124

125 **Nature and Rationale for Model Improvements**

126 In REACH terminology, the TRA is a Tier 1 tool [12], i.e. it is intended to provide simple, yet conservative
127 estimates of (inhalation and dermal) exposure sufficient for an user to determine whether a more
128 detailed (Tier 2) exposure assessment may be required or not. For worker exposures, the structure of
129 the TRA has been developed along the lines of a source receptor model, such that account can be taken,
130 as required under REACH, of how different workplace conditions (OCs) and forms of exposure control
131 (RMMs) affect exposure. Figure 1 illustrates this basic form for inhalation exposure predictions.

132 A broad summary of the suggestions that were provided by TRA v2 users for improvement to the worker
133 element of the TRA is listed in Table 1, together with those suggestions that were taken forward for
134 incorporation in TRA v3. They are categorized according to their relationship to the element of the
135 source receptor chain that they are most closely related to. The user suggestions represent a variety of
136 aspirations, ranging from practical suggestions for improving the inherent sensitivity and specificity, to
137 extending the TRA v2 beyond its stated domain of application. Apart from the technical suggestions for
138 improvement listed in Table 1, users expressed their overwhelming support for how the TRA v2 was
139 positioned and structured i.e. as a single tool that is capable of delivering estimates of exposure as
140 required by REACH (i.e. the capability to account for any differences in inhalation and dermal estimates
141 that result from different industrial and professional uses). This indicated that a prime consideration
142 that ECETOC needed to account for in any revision was to identify if the model's accuracy and flexibility
143 should be further improved, without radically overhauling its basic structure.

144 The TRA v2 has a boundary of reliable application that has been previously described [8]. But the
145 paradox of 'user friendly' tools is that they are used by a wide range of ability levels that, in turn, have a
146 range of (sometimes competing and contradictory) expectations for the tool. Indeed, where a tool's
147 boundaries are more restricted than the user's expectations, then this does not always seem to serve as
148 a constraint to users seeking to apply the tool outside the stated domain. Some of the suggestions in
149 Table 1 are possibly a reflection of this fact. So while some represent straightforward suggestions that
150 aim to improve the technical basis of the tool, others seek to extend its boundaries in ways that are
151 inconsistent with its underpinning principles (viz founded on proven scientific principles; broadly

152 applicable across a range of substance types/properties; directly REACH relevant; conservative in its
153 outputs; and simple to access and apply).

154 In order to determine which improvements could be accounted for, ECETOC therefore considered each
155 of the suggestions within the context of these principles. Table 1 also identifies those that were chosen
156 to be incorporated in TRAv3 and those that were not, together with a brief explanation of why those
157 suggestions not taken forward were rejected. In the main, those discarded fell into 3 categories: 1) that
158 the proposals were not broadly applicable across the uses (REACH process categories, PROCs) covered
159 by the TRA; 2) that the measures were technically valid but were associated with sophisticated
160 engineering or management strategies, which are inconsistent with the expectations of a Tier 1 model
161 under REACH; and 3) that the scientific rationale supporting the proposed solution was considered
162 insufficient for inclusion within the model (i.e. the associated uncertainties were too high to be included
163 in a Tier 1 tool). A further consideration was the need, identified by several key users, for the TRA to
164 align as far as possible with the broader 'scope expectations' of the relevant REACH Technical Guidance.
165 In this respect, changes were also introduced that enable short-term inhalation exposure values to be
166 calculated from the shift average estimates according to the methodology contained within the TGD, in
167 order that these can then be compared to available short-term DNELs. In the case of dermal exposures,
168 more extensive revisions were introduced (Fig.2) which were driven by the significant gap between the
169 ability of the inhalation and dermal modules in version2 of the TRA to account for REACH OCs and
170 RMMs. The result is that in version3, the two modules are now more closely aligned, albeit that there
171 remains less flexibility in the assessment of dermal exposures, i.e. ECETOC considered that the available
172 science is not sufficient to reliably support the ranges of OCs and RMMs linked to inhalation exposures
173 (Fig. 1) or to predict short term exposures.

174 **Discussion**

175 The ECETOC TRA is not a sophisticated model in terms of the means it employs to predict exposure. In
176 essence, it is a source receptor model that has been modified and optimised to accommodate the
177 broader requirements of REACH [13]. Because it is specifically targeted towards REACH, the TRA has
178 acquired a diverse user community, ranging from experts in large established organisations to users in
179 small and medium sized enterprises. Indeed, the fact that the TRA has been specifically targeted for
180 REACH may go some way towards explaining the fact that TRA has been used in so many REACH
181 Registrations. However, despite its intended attributes, it does not address every eventuality. In this
182 context, the applicability domain of the TRA has been described and, in addition, the tool incorporates
183 integral information (in the form of pop-ups) that is intended to further help users correctly use the tool.
184 Experience, however, suggests that despite such accompanying warning advice, some users will try to
185 adapt it (either intentionally or in ignorance) to situations that lie outside the domain of the tool.

186 In this sense every exposure model has its strengths and weaknesses. More sophisticated models (often
187 termed Tier 2 models) invariably have greater accuracy and more developed outputs such as confidence
188 intervals around point estimates, but are invariably less accessible to non-expert users (such as those
189 downstream groups that are often associated with REACH) and, perhaps as a consequence, can be
190 associated with greater between user variability [14]. Furthermore, since these models are often only

191 applicable to defined use types or exposure routes, they often are linked to a more restricted domain
192 than Tier 1 models. These factors perhaps explain the reason why REACH advises registrants to apply
193 available models in a tiered and targeted manner, accounting for the limitations of each model.

194 Table 1 indicates that two types of suggestions proposed by users were: 1. revisions (mostly
195 downwards) to the TRA's base exposure predictions (and particularly those for dermal exposures), and
196 2. suggestions for expanding the tool by extending the range of exposure determinants (termed
197 operational conditions (OC) and risk management measures (RMM) by REACH) that the TRA
198 incorporates. Concerning the first suggestion, even though the process of developing the TRA v2
199 introduced significant revisions to the TRA v1 exposure estimates, there has been no comprehensive
200 independent validation of the TRA v2 predictions. Limited evaluation of parts of the tool [15,16,17],
201 coupled with the anecdotal experiences of 2010 Registrants, suggest that the inhalation estimates for
202 volatile liquids are, in the main, conservative reflections of reality. In the case of dermal exposures,
203 there is a paucity of reliable and representative measured data against which models can be compared.
204 For this reason, ECETOC decided that it would not substantially revise the base TRA v2 exposure
205 predictions in v3 but await the findings of the larger BAuA funded E-Team project that is intended to
206 validate the range of available REACH worker exposure models (<http://www.eteam-project.eu/>).
207 However, concerning the second type of suggestion, ECETOC determined that it would expand the TRA
208 to incorporate new exposure modifiers (OCs and RMMs) provided that they remained in line with the
209 screening nature of the tool and followed the same principles as those applied for inhalation exposure
210 estimation, i.e. that they were capable of application across the range of use scenarios (PROCs) covered
211 by the TRA, were straightforward to apply and that there was a convincing underpinning scientific
212 rationale. It was also agreed that ECETOC would correct anomalies regarding how the exposure
213 predictions for certain PROCs were identified. The implemented changes (for inhalation and dermal
214 exposures respectively) are summarized in Figures 1 and 2.

215 Previous research on how target audiences respond to health and safety communications has shown
216 that the responses and expectations of these groups are shaped not only by their understanding (or lack
217 of understanding) of the technical basis of the information itself (in this case the TRA model), but also by
218 other factors that relate to their 'needs' [18]. For this reason, it is perhaps unsurprising that Table 1
219 includes suggestions that may at face value appear misplaced: the suggestions simply reflect the
220 expectations that these groups would like any REACH model to deliver. For example, while some
221 suggestions represent incremental improvements to the TRA within its existing domain, others have
222 limited application or are at odds with the expectations of REACH (and in particular those laid out in the
223 relevant Technical Guidance Documents). In the former case, ECETOC was receptive to the inclusion of
224 such ideas, but ECETOC did not accommodate any suggestions that would be seen to be at variance with
225 REACH. This is not to say though that not all the 'in scope' improvements were implemented. For
226 example, where a valid exposure control was only applicable to a sector specific use or type of
227 substance e.g. a vapour recovery system during tanker loading, then this was not included. Similarly, if
228 the available science for the suggestion was considered weak (even though the basic thesis may be
229 attractive), then this was rejected too e.g. the suggestion that the dustiness of a substance is a
230 legitimate predictor of dermal exposure.

231 The changes implemented in TRA v3 should result in it being an improved model compared to v2.
232 Because the tool has been applied in REACH registrations, it is important to gauge whether these
233 changes undermine in any way the integrity of registrations that have been based upon the TRA v2. The
234 fact that the improvements are essentially enhancements to the tool's utility (the addition of OCs and
235 RMMs) and not material differences in its core exposure prediction framework means that v2-based
236 CSRs remain valid i.e. v2 was not deficient in any material way, rather it was capable of further
237 refinement, especially in the flexibility it offered users. Indeed, within the context of REACH, there is
238 probably no 'best' model. Users normally need to have access to a range of models to address the
239 breadth of expectations demanded by REACH. The TRA is aimed as a Tier 1 (screening) model, i.e. its
240 prime purpose is to identify situations (Exposure Scenarios) of 'no concern' and target those where
241 higher tier approaches to evaluation should be applied. As a consequence, the TRA is unlikely to deliver
242 the most accurate exposure estimates among available REACH models: by definition they are intended
243 to be inherently conservative. The TRA v3 has retained the v2 structure that enabled the inputs to and
244 outputs from the tool to be readily processed into REACH CSAs and Exposure Scenarios something that
245 allows for work flow efficiencies to be derived from the process of chemical safety assessment, ES
246 writing for registration dossiers and ultimately ESs for extended Safety Data Sheets.

247 One of the dilemmas of exposure tools could be said to be that enhancing their accessibility invariably
248 demands simplicity in the associated user interfaces. In turn, this militates against model complexity.
249 But, often, complexity is associated with increasing sensitivity. To compensate for this conundrum,
250 REACH encourages a range of exposure tools to be applied in the development of CSRs. But, it is
251 apparent that despite the comparatively straightforward domain statements in the TRA, a wide number
252 of users either misunderstand or ignore them. Several of the suggested improvements specifically deal
253 with topics outside the stated domain of the TRA (e.g. liquid aerosols and metal fumes). Therefore,
254 version 3 not only includes a clearer written domain statement but has also been structured to
255 incorporate a series of active features (e.g. 'pop ups') that serve to warn or remind users of the TRA's
256 limitations when they try to enter counter-intuitive information, e.g. higher efficiency ventilation or
257 respiratory protection is not permitted for professional uses; LEV cannot be applied outdoors. Table 2
258 describes the domain of version3 and will hopefully not only serve to constrain the creativity exhibited
259 by some version2 users, but also to further reduce intra- and inter-user variability.

260 At the basic level, any model should be regularly reviewed to identify if it is capable of offering improved
261 accuracy and/or flexibility. But as changes to the models used in regulatory settings can also initiate the
262 need to re-work regulatory submissions that rely on the model, then improvement for the sake of it
263 should clearly be avoided. When a revision to a model results in its ability to identify new or better
264 describe existing risks, then such a change is clearly warranted. However, it is difficult to prospectively
265 determine the potential impact of possible improvements. Those that result in no material change to
266 the risk assessment outcome must clearly be considered to be of questionable value. In this respect it
267 would appear appropriate for models having regulatory application (such as those referred to within
268 REACH) to be reviewed and maintained. What might represent an appropriate frequency for such
269 reviews is unclear, but it perhaps might align with the frequency of the parent legislation (i.e. 5 years in
270 the case of REACH). As the TRA revision exercise perhaps illustrates, it is comparatively straightforward

271 to propose new models, but is much more challenging to sustain them over the associated regulatory
272 timescales.

273

274 **Conclusions**

275 The scientific basis of exposure models varies according to the intentions and characteristics of the
276 model. At face value, those models that are built on established scientific foundations may not require
277 regular review and revision. However, exposure models seldom operate in isolation. Indeed, some
278 models (such as the TRA) have been primarily developed to support particular regulatory frameworks
279 and needs. But as chemicals regulation is invariably dynamic, then it is important that the review period
280 for those models that are intended to be used in regulatory arenas, is more frequent as one of the
281 express aims should be to ensure that the model remains optimised for the regulatory space which it is
282 intended to operate.

283 Following the release of the TRA v2 in 2009, ECETOC has completed an assessment of those elements of
284 the TRA that require update in order that the tools remains suitable for use under REACH, the exception
285 being the accuracy (or not) of its inhalation and dermal exposure estimates that are being addressed by
286 the wider E-Team project. The potential improvements to the TRA suggested by its users indicate that
287 lower tier models not only need to be based on established scientific principles but also need to be
288 robustly structured in order to address the likelihood that users will try to apply such models outside
289 their domain of reliability. Indeed, in such cases, it would appear that simple 'boundary statements' may
290 be insufficient in themselves and that more active approaches to limit such tendencies may be
291 advisable. The ECETOC experience also highlights the fact that the process for model update is not
292 simply one of accommodating scientific and technical advances; in conjunction with any intention to
293 implement a change, model developers must also understand the implications of further model updates
294 on the regulatory environment in which the model operates. For example, will the revised version bring
295 new responsibilities for users or serve to potentially undermine the integrity of prior decisions arrived at
296 using previous versions of the model? Conversely, when new or existing models are intended to be
297 introduced into existing regulatory frameworks then it would appear sensible for such 'regulatory
298 impact analyses' to be available to accompany the model and suitably inform prospective users of
299 potential pitfalls and responsibilities that they should be aware of. In this respect, it is advisable that the
300 process for revising model of this type is sufficiently transparent and comprehensive to document such
301 considerations, as the benefits of communicating the rationale for and consequences of any changes as
302 part of the roll out of any revised version of the model are self-evident. There would also appear to be a
303 benefit in ensuring that the processes adopted by developers when revising models (and particularly
304 those targeted at common or similar regulatory needs) are harmonised in order that the users are able
305 to obtain consistent 'impact assessments'. Clearly, change for the sake of change should be avoided.

306 Users of models are also not without responsibilities. The suggestions put forward by TRA users appear
307 to indicate that most are well aware of their obligations when deploying the TRA within REACH. But
308 some appear less well-informed. In this respect model developers would appear to have ongoing

ECETOC TRA version 3 : Capturing and Consolidating the Experiences of REACH

309 responsibilities to sustain their models, both through regular technical review but also via activities
310 aimed at describing the nature of user experiences. The integrity of models applied in regulatory
311 settings is not solely a function of the inherent capabilities of the model, but also how the model is
312 routinely applied. Historically, significant attention has been paid to the former, but the latter area is
313 equally important if any outputs are to be both reliable and consistent. Success is not just therefore a
314 function of the model *per se*, but is also shaped by the nature of how it can be understood and applied.

ECETOC TRA version 3 : Capturing and Consolidating the Experiences of REACH

315 **Titles of Figures and Tables**

316 Figure 1 : Structure of the ECETOC TRA model (inhalation exposures)

317 Figure 2 : Structure of the ECETOC TRA model (dermal exposures)

318 Table 1 : Summary of suggested and adopted improvements to the TRA version2

319 Table 2 : Domain of reliable application of the ECETOC TRA version3

320

321 Table 1: Summary of suggested and adopted improvements to the TRA version2

322

Affected Element of TRA	Suggested Area for Improvement	Within Scope of TRAv2	Nature of Changes in TRAv3
<p>Core Model Determinants</p>	<ul style="list-style-type: none"> Ensure that any differences between the exposure estimates for industrial and professional users are suitably differentiated 	Yes	<ul style="list-style-type: none"> Identified anomalies now corrected
	<ul style="list-style-type: none"> When relevant, ensure that same ventilation effectiveness applies to both inhalation and dermal estimates 	Yes	<ul style="list-style-type: none"> Identical values apply to both forms of estimate
	<ul style="list-style-type: none"> Suggestions that several core estimates are too conservative (e.g. PROCs 7 and 11) and require downward revision 	Yes	
	<ul style="list-style-type: none"> Introduce consideration of the potential impact of volatility/dustiness on dermal exposure estimates 	No	<ul style="list-style-type: none"> Not implemented. Awaiting outcome of E-Team validation project.
	<ul style="list-style-type: none"> Introduce ability to characterize exposures from UVCBs (substances of unknown and variable composition) 	No	<ul style="list-style-type: none"> Not implemented. Current scientific basis considered insufficient to justify inclusion
	<ul style="list-style-type: none"> Extend the TRA to include an ability to predict aerosol (mist) exposures and process fumes 	No	<ul style="list-style-type: none"> Not implemented. Current scientific basis considered insufficient to justify inclusion.
	<ul style="list-style-type: none"> Introduce further discrimination in the TRA to better predict the nature of exposures to liquids having very low vapour pressures 	No	<ul style="list-style-type: none"> Warning message now included in tool.
	<ul style="list-style-type: none"> Exposure estimates should apply to all industry sectors (REACH PROCs) 	No	<ul style="list-style-type: none"> New functionality incorporated for certain substances with vapour pressure of < 0.01 Pa
<p>Operating Conditions</p>	<ul style="list-style-type: none"> Introduce ability to predict exposures at different operating temperatures (i.e. beyond ambient) 	No	<ul style="list-style-type: none"> Implemented via input of VP at elevated temperature
		No	<ul style="list-style-type: none"> Implemented with four duration and concentration

	<ul style="list-style-type: none"> Introduce consideration of the potential impact of task duration and concentration of substance in product/preparation when applied to dermal exposure estimates 		bands (same as for inhalation)
Risk Management Measures	<ul style="list-style-type: none"> Include the capability to account for the effectiveness of general ventilation on inhalation exposure estimate Include the capability to account for LEV use outdoors on inhalation estimates Incorporate the ability to address the effectiveness of dermal protection (gloves) Incorporate the ability to address the impact of specific working training on inhalation/dermal estimates Include a function to address the impact of specific work equipment and procedures e.g. film isolators, drum pumps, remote handling, etc. Provide the ability to factor in 'enhanced' exposure controls i.e. RPE and extraction ventilation beyond TRAv2 upper bounds (typically 90%) 	Partly No No No No No	<ul style="list-style-type: none"> TRAv3 includes ability to account for two different forms of general ventilation Not implemented as the use of LEV outdoors is not an appropriate Tier 1 consideration TRAv3 now incorporates this feature Not implemented. Proposed solutions considered too scenario specific for incorporation into a general exposure model Not implemented. Proposed solutions considered too scenario specific for use in a general exposure model Not implemented. TRA is a Tier1 model and does not consider effectiveness >95%.

323

324

ECETOC TRA version 3 : Capturing and Consolidating the Experiences of REACH

325 Table 2: Domain of reliable application of the ECETOC TRA version3

326

Domain Boundary	Comments
Gases	The TRA does not predict exposure to gases. However the TRA does allow exposures to very volatile liquids (with no upper bound set on vapour pressure) to be estimated. As these very volatile liquids might be assumed to be the equivalents of gases for many circumstances of use (PROCs), then provided users are able to assure themselves of such equivalencies, then it is reasonable to assume that the high volatility exposure prediction can also be used to predict exposures to gases in certain scenarios.
Aerosol mists	Although exposures aerosol mists might be expected to be associated with certain uses which are open and associated with the release of significant amounts of energy (e.g. spraying, machining, etc), the TRA does not address such exposures. However, in circumstances where users have available representative measured exposure data on mists, then these may be able to be used to 'calibrate' and read across to relevant PROCs.
Process fumes	Although exposures to process fumes might be expected to be associated with certain uses which are undertaken at elevated temperatures (e.g. handling hot materials when their melting point lies at or above ambient temperatures), the TRA does not address such exposures.
Fibrous materials	The TRA does not predict exposure to fibrous solids.
Exposures above ambient temperature	The TRA predicts exposure at 20°C. Where a liquid substance is handled at temperatures significantly in excess of this, then users should apply the vapour pressure calculated at the operating temperature. The exception to this 'rule' is PROC6 (calendarling) where the TRA predictions already account for the elevated temperatures applied in this activity (see also 'process fumes' above when solid substances are handled).
Solids in liquids	The TRA cannot predict exposures to solids suspended or dissolved in liquids. If such exposures are considered relevant, then in circumstances where users have available representative measured exposure data, then these may be able to be used to 'calibrate' and read across to relevant PROCs, or alternatively users are referred to other tools capable of estimating such exposures.
CMRs and 'very high hazard' substances e.g. respiratory sensitisers	Although the TRA is a Tier 1 model and hence is conservative in the nature of its predictions, it requires judicious application to CMRs and other high hazard substances. However, for 'simple' mono-constituent substances such as readily volatile liquids (e.g. toluene, benzene, n-hexane), then provided users can assure themselves that the exposures lie within the domain boundaries, the TRA will be capable of offering valid predictions.
UVCBs	The TRA estimates have been developed for mono-constituent substances. Where UVCB substances are being assessed using the TRA (in particular those substances having a range of volatilities) then users should apply the nominal VP for the substance (or the VP of most volatile component present at >1% when this is known
Mixtures	The concentration modifier enables the TRA to predict exposures to a single substance within a (simple) mixture. However, the TRA is not intended to be applied to calculate combined exposures to different substances in a mixture beyond the 'concentration banding' that already exists.
Fractions of airborne solids	The TRA exposure predictions for solids do not differentiate between total inhalable exposure (respirable and non-respirable) and respirable exposures fractions. Users should therefore assume that any output for solids describes the inhalable fraction.
Out of scope uses	The TRA does not cover certain REACH uses (PROCs), specifically PROC 25 (handling of solid inorganic substances at ambient temperature); PROC 26 (Handling of solid inorganic substances at ambient temperature), PROC 27a (production of metal powders using hot processes) and PROC 27b (production of metal powders using wet processes). If these PROCs are considered relevant, then users are referred to other tools capable of estimating exposure in these circumstances (e.g. MEASE).


327

328 **References**

- 329
- 330 1. EC. Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18th December
- 331 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
- 332 establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council
- 333 Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive
- 334 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC. Office
- 335 for Official Publications of the European Communities, Luxembourg. 2006 [http://eur-](http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32006R1907:EN:NOT)
- 336 [lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32006R1907:EN:NOT](http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32006R1907:EN:NOT)
- 337
- 338 2. ECETOC. Targeted Risk Assessment. Technical Report No. 93. European Centre for Ecotoxicology
- 339 and Toxicology of Chemicals, Brussels, Belgium. 2004
- 340
- 341 3. C. Money, C. de Rooij, F. Floc'h, S. Jacobi, P. Koundakjian, S. Lanz, M. Penman, C. Rodriguez, and G.
- 342 Veenstra. Policy and Practice in Health and Safety 2004 **1** : 43-65
- 343
- 344 4. ECHA. Guidance on information requirements and chemical safety assessment, Chapter R12: Use
- 345 [Descriptor System, European Chemicals Agency, Helsinki, Finland. 2010](http://echa.europa.eu/documents/10162/13632/information_requirements_r12_en.pdf)
- 346
- 347 5. C. Money, S. Jacobi, M.G. Penman, C. Rodriguez, C. De Rooij and G. Veenstra. Journal of Exposure
- 348 Science & Environmental Epidemiology. 2007 **17**:S67-S71.
- 349
- 350 7. H. Marquart, C. Northage and C. Money C. Journal of Exposure Science and Environmental
- 351 Epidemiology. 2007 **17**, S16–S25
- 352
- 353 8. ECETOC. Addendum to ECETOC Targeted Risk Assessment Report No. 93. Technical Report No. 107.
- 354 European Centre for Ecotoxicology and Toxicology of Chemicals, Brussels, Belgium. 2009
- 355
- 356 9. ECHA. REACH Technical Guidance on information requirements and chemical safety assessment,
- 357 [Chapter R14: Occupational Exposure Estimation, European Chemicals Agency, Helsinki, Finland. 2012](http://echa.europa.eu/documents/10162/13632/information_requirements_r14_en.pdf)
- 358
- 359 10. EUROSTAT. The REACH baseline study: 5 years update, European Union, Luxembourg. 2012
- 360 http://epp.eurostat.ec.europa.eu/cache/ITY_OFFPUB/KS-RA-12-024/EN/KS-RA-12-024-EN.PDF
- 361
- 362 11. C. Money, A. Margary, D. Noij and K. Hommes (2011). Ann Occup Hyg. 2011 **55** (5): 451-464.
- 363
- 364 12. ECHA. REACH Technical Guidance on information requirements and chemical safety assessment,
- 365 Part D: Exposure Scenario Building, European Chemicals Agency, Helsinki, Finland. 2012
- 366 http://echa.europa.eu/documents/10162/13632/information_requirements_part_d_en.pdf


ECETOC TRA version 3 : Capturing and Consolidating the Experiences of REACH

- 362 13. ECETOC. ECETOC TRA version 3: Background and Rationale for the Improvements. Technical Report
363 No. 114. European Centre for Ecotoxicology and Toxicology of Chemicals, Brussels, Belgium. 2012
- 364 14. P.E. McDonnell, J.M. Schinkel, M.A. Coggins, W. Fransman, H. Kromhout, J.W. Cherrie and E.L.
365 Tielemans, *J. Environ. Monit.*, 2011, **13**, 1597-1606
- 366 15. S.R. Vink, J. Mikkers , T. Bouwman, H. Marquart and E.D. Kroese. *Regulatory Toxicology and*
367 *Pharmacology*; 2010 **58**(1):64-71.
- 368 16. M. Kupczewaka-Dobacka, S. Czerczak. and M. Jakubowski. *International Journal of Occupational*
369 *Medicine and Environmental Health*; 2011 **24**(2):208-217.
- 370 17. E. Hofstetter, J.W. Spencer, K. Hiteshew, M. Coutu and M. Neally. *M. Ann. Occup. Hyg.* 2013 **57**, 210–
371 220,
- 372 18. I. Vickers, R. Baldock, D. Smallbone, P. James and I.Ekanem. *Cultural influences on health and safety*
373 *attitudes and behaviour in small businesses*, Research Report 150, HSE Books, Norwich, 2003
374 <http://www.hse.gov.uk/research/rrpdf/rr150.pdf>



Italicised text represents TRA v2 functionality. Bold text indicates TRAv3 enhancement

Figure 1 : Structure of the ECETOC TRA model (inhalation exposures)
254x190mm (96 x 96 DPI)



Italicised text represents TRA v2 functionality. Bold text indicates TRAv3 enhancement

* applies to all PROCs for high and moderate volatility liquids and non-dusty solid substances

Figure 2 : Structure of the ECETOC TRA model (dermal exposures)
254x190mm (96 x 96 DPI)

ECETOC TRA version 3 : Capturing and Consolidating the Experiences of REACH

1 **ECETOC TRA version 3 : Capturing and Consolidating the Experiences of REACH**

2

3 Environmental Impact Statement

4

5 Version 2 of the ECETOC targeted risk assessment (TRA) exposure model was released in 2007 and over
6 10,000 users have subsequently downloaded the model. The TRA v2 has subsequently been applied to
7 assess worker, consumer and the environmental risks in over 80% of the REACH registrations in the EU.
8 But like all models, it is capable of further improvement. This work describes the experiences resulting
9 from the development of the TRAv3 and particularly those considerations that are relevant for those
10 exposure models aimed at 'non-expert' groups, in order that such models can be reliably and
11 consistently applied.

ECETOC TRA version 3 : Capturing and Consolidating the Experiences of REACH

Chris Money, Frank Schnoeder Dook Noij, Hsieng-Ye Chang, and Jan Urbanus

Table of Contents

- Background
- Methods
- Nature and Rationale for Model Improvements
- Discussion
- Conclusions

This article outlines the pertinent considerations when developing and sustaining exposure models that are intended for use in regulatory processes.

